KIMBERLY WOODLIFF: Open Payments
NPI 1699309393 · WACO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,184 in 73 payments from 12 companies in 2025. Trend: 2023 $839 · 2024 $1,317 · 2025 $3,184
Food & beverage: $2,054Consulting: $732Education: $398
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 21 | $1,857 |
| GlaxoSmithKline, LLC. | 22 | $443 |
| Actelion Pharmaceuticals US, Inc. | 7 | $325 |
| Regeneron Healthcare Solutions, Inc. | 8 | $269 |
| SANOFI-AVENTIS U.S. LLC | 1 | $100 |
| AstraZeneca Pharmaceuticals LP | 3 | $49 |
| Phathom Pharmaceuticals, Inc. | 5 | $46 |
| Electromed, Inc. | 2 | $28 |
| United Therapeutics Corporation | 1 | $21 |
| Verona Pharma, Inc. | 1 | $16 |
Products named: DUPIXENT, NUCALA, OPSUMIT, TRELEGY ELLIPTA, UPTRAVI, VOQUEZNA, BREZTRI, SMARTVEST.
Industry payments across TX — which companies pay providers there.
